Systematischer Algorithmus für maschinelles Lernen zur schnellen Thromboseerkennung (DVT-SMART)
Bewertung einer neuen diagnostischen Strategie für vermutete DVT, bestehend aus Point of Care D-Dimer, AI-basiertem Vorhersagemodell und Komprimierungsultraschall
The goal of this clinical trial is to compare the use of a machine learning-based algorithm and point-of-care D-dimer to laboratory D-dimer and compression ultrasound to exclude deep vein thrombosis in the under extremities in patients referred to a medical department suspected of having deep vein thrombosis. The main aim is to answer are if a machine learning algorithm and point of care D-dimer can exclude deep vein thrombosis in more patients than clinical assessment and D-dimer alone.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
All participants will follow the usual diagnostic algorithm used for patients with suspected DVT referred to Ostfold Hospital (all patients are examined by a physician, D-dimer is analyzed in all patients, ultrasound is performed by a radiologist in patients with positive D-dimer). In addition to usual care, POC D-dimer, POC ultrasound (performed by ED physicians), blood sampling for biobanking, and photographies of the under extremities will be performed. The machine learning model will be tested to see if the prediction is correct. In participants where ultrasound is performed, it will also be assessed whether the machine learning algorithm could have excluded the participant without the use of ultrasound. None of the additional procedures will have any impact on the patient diagnostics or treatment.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Waleed Ghanima, Professor
- Telefonnummer: 0047 69860000
- E-Mail: waleed.ghanima@so-hf.no
Studieren Sie die Kontaktsicherung
- Name: Hans Joakim Myklebust-Hansen, Medical Doctor
- Telefonnummer: 0047 97501765
- E-Mail: hans.joakim.hansen@so-hf.no
Studienorte
-
-
-
Sarpsborg, Norwegen, 1714
- Rekrutierung
- Østfold Hospital Trust
-
Kontakt:
- Hans J Myklebust-Hansen, M.D.
- Telefonnummer: 004797501765
- E-Mail: hansjoakim_mh@outlook.com
-
Unterermittler:
- Hans J Myklebust-Hansen, M.D.
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patients referred to the ED due to suspicion of DVT
- Age ≥ 18 years
- Able to give informed consent
Exclusion Criteria:
- Ongoing use of anticoagulation for more than 72 hours
- Previous participation in the study
- Life expectancy of less than three months.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Diagnose
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: All participants
All participants will be treated the same way. |
POC D-dimer will be compared to laboratory D-dimer in hospital setting and used in a machine learning model Point of care (POC) ultrasound performed by ED physicians compared to ultrasound performed by radiologist. POC ultrasound 3 point examination performed by ED physician will be compared with POC ultrasound full leg examination performed by ED physician. The DSS will be compared to the usual strategy. It will also be estimated how many participants where DVT could have been excluded without ultrasound.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Safety of the new strategy (POC D-dimer, ML-based prediction model, POC CUS by emergency physician)
Zeitfenster: From enrollment to the end of the primary assessment period (90 days)
|
Evaluate the safety of a new strategy consisting of POC D-dimer and an ML-based prediction model followed by CUS performed by emergency physicians by comparing the new strategy's safety with our standard care by measuring the proportion of patients in whom DVT is excluded according to the new strategy but was diagnosed with DVT by standard care or in whom DVT is diagnosed within the 90-day follow up. |
From enrollment to the end of the primary assessment period (90 days)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Evaluate the efficiency of the new strategy
Zeitfenster: From enrollment to the end of the primary assessment period (90 days)
|
The proportion of patients in whom DVT can be ruled out by the ML-based prediction model with POC D-dimer compared to the efficiency of Wells score and laboratory D-dimer |
From enrollment to the end of the primary assessment period (90 days)
|
|
Validate the safety and efficiency of the ML-based prediction model
Zeitfenster: From enrollment to the end of the primary assessment period (90 days)
|
Safety will be determined by the proportion of patients in whom DVT is excluded by the ML-model but diagnosed by standard care. Efficiency will be determined by the proportion of patients in whom DVT can be excluded by the ML-based model |
From enrollment to the end of the primary assessment period (90 days)
|
|
Evaluate concordance between CUS performed by emergency physicians and radiologists.
Zeitfenster: From time of enrollment until time of ultrasound examination performed by radiologist, assessed up to 48 hours.
|
Determine the proportion of false negative and false positive diagnosis of DVT in emergency physician-performed ultrasound compared with ultrasound performed by radiologists. |
From time of enrollment until time of ultrasound examination performed by radiologist, assessed up to 48 hours.
|
|
Evaluate concordance between POC D-dimers in an ED setting and laboratory D-dimers.
Zeitfenster: From enrollment to the completion of D-dimer analysis, assessed up to 24 hours.
|
Compare the two POC D-dimers with the STA-Liatest D-dimer and Siemens INNOVANCE by direct comparison of the true/false positive/negative results. |
From enrollment to the completion of D-dimer analysis, assessed up to 24 hours.
|
|
Evaluate the hypothetical time to be completed for the novel strategy compared to the standard strategy.
Zeitfenster: From time of enrollment until time of discharge from the emergency department either discharged from the hospital or hospitalized, assessed up to 24 hours.
|
Estimating the total management time defined as time from ED registration to ED discharge in patients evaluated according to the new strategy compared to standard care. |
From time of enrollment until time of discharge from the emergency department either discharged from the hospital or hospitalized, assessed up to 24 hours.
|
|
Evaluate the safety of a limited ultrasound protocol (two-point and proximal) compared to full-leg CUS performed by emergency physicians and radiologists
Zeitfenster: 90 days after enrollment.
|
Estimating the proportion of patients in whom DVT was ruled out by the limited ultrasound protocol but was diagnosed with DVT by the whole-leg ultrasound. |
90 days after enrollment.
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 682139
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
The plan to share IPD with other researchers are not yet decided because it has not yet been discussed.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .